Savolitinib is a Small Molecule owned by Hutchison MediPharma, and is involved in 36 clinical trials, of which 18 were completed, 14 are ongoing, and 4 are planned.
Savolitinib (AZD-6094) acts as selective c-Met inhibitor. The c-Met signalling pathway has specific roles particularly in normal mammalian growth and development, and this pathway function abnormally in a range of different cancers. c-Met signaling is implicated in a wide variety of human malignancies. The c-Met pathway activates a program of cell dissociation and motility coupled with increased protease production that has been shown to promote cellular invasion through extracellular matrices and that closely resembles tumor metastasis. The drug candidate, by antagonizing c-Met receptor, elicits the therapeutic intervention.
The revenue for Savolitinib is expected to reach a total of $60.1bn through 2028. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Savolitinib NPV Report.
Savolitinib (Orpathys) is a potent antineoplastic agent. It is formulated as tablets for the oral route of administration. Orpathys is indicated for the treatment of patients with non-small cell lung cancer who have progressed following prior systemic therapy or are unable to receive chemotherapy.
Savolitinib (AZD-6094) is under development for the treatment of gastric cancer, adenocarcinoma of the gastroesophageal junction, papillary, metastatic castration-resistant prostate cancer, non-small cell lung cancer, advanced or metastatic pulmonary sarcomatoid carcinoma, metastatic colorectal cancer. The drug candidate is administered orally. Volitinib acts by targeting ATP-competitive c-Met receptor.
It was also under development for primary CNS tumors including medulloblastoma, high-grade glioma and diffuse intrinsic pontine glioma, solid tumors, clear cell renal cell carcinoma, breast cancer and hepatocellular carcinoma
Hutchmed China Overview
Hutchmed China (Hutchmed) formerly known as Hutchison China MediTech is a biopharmaceutical company which discovers, develops, manufactures and commercializes drugs for the treatment of solid tumors and hematological malignancies; and immunological disorders. It also offers over-the-counter (OTC) pharmaceuticals and consumer healthcare products. Hutchmed also provides R&D services to other companies. It has a broad pipeline of drug candidates indicated for the treatment of immunological diseases, besides novel oral drug candidates for various cancers and inflammation. It operates in China, North America, Europe and Australia. The company offers prescription drugs to hospitals in China through direct sales force. It distributes consumer health products in China. Hutchmed is headquartered in Kowloon, Hong Kong.
The company reported revenues of (US Dollars) US$356.1 million for the fiscal year ended December 2021 (FY2021), an increase of 56.2% over FY2020. The operating loss of the company was US$207 million in FY2021, compared to an operating loss of US$196.7 million in FY2020. The net loss of the company was US$194.7 million in FY2021, compared to a net loss of US$125.7 million in FY2020.
Quick View – Savolitinib
|Highest Development Stage|